Nkarta Inc Stock News

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeutics market is expected to grow to $17.5 billion by 2032. NKX019 has a better shot at being effective towards autoimmune disorders, because of several factors like no antigen escape, lower cell bur...

Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019.

This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024.

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sponsored trial (“IST”) of NKX019, Nkarta's allogeneic, CD19-directed chimeric antigen receptor (CAR) ...

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Exe...

For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.